My Ocrevus Treatments: The Next Round Is Delayed
By now, I had planned to give you an update on my current multiple sclerosis disease-modifying therapy Ocrevus (ocrelizumab). But one thing living with multiple sclerosis teaches us is to…
Engaging Thoughts
— Laura Kolaczkowski
Laura Kolaczkowski comes from Beavercreek, Ohio, and worked at the University of Dayton for over 25 years until MS challenged her enough to go onto full-time disability. She is active in the MS community on multiple levels, and writes for her own personal blog, InsideMyStory and as a patient expert for MultipleSclerosis.net. Laura is the Lead Patient Representative and co-principal investigator for iConquerMS™, a patient powered MS research network. Laura freely admits her Liberal Arts background fuels her interest in patient engagement and empowerment and she struggles with the science of MS.
Featured Post
My Travel Tips for Those with MS Mobility Problems
I love to travel and see new sights, but my multiple sclerosis (MS) mobility problems present particular challenges. Over time I have accumulated my own set of travel tips. Perhaps some of the…
Read more
Laura Kolaczkowski -- Engaging Thoughts
My Holiday Gift Wish
It’s that time of year when everyone is asking: What would you like for Christmas? Shopping for the perfect gift for me is a challenge because I’ve been around long enough to have…
Advances in MRI Readings
My neurologist orders an annual MRI to see if any major changes have occurred, and last year my imaging included NeuroQuant software. NeuroQuant is still relatively unknown in the multiple sclerosis patient community.
A JC Virus Primer
There is often alarm and confusion about the JC virus, how we get it, and what it means to people with multiple sclerosis. This is my quick primer to help address these questions…
Ocrevus Q&A, Part 2
Editor’s note: This is the second of a two-part series on readers’ comments about Ocrevus (ocrelizumab). Read part one here. Last week, I responded to a few comments on columns…
Ocrevus Q&A, Part 1
Editor’s Note: First in a two-part series on readers’ comments about Ocrevus (ocrelizumab). I switched disease-modifying therapies and began treatment with Ocrevus (ocrelizumab) in June. I previously wrote about my…
How Doctors’ Gender Can Influence Opinions on Healthcare Quality
There are two doctors. Here’s your choice: One has a patient-centered approach to care, spends more time with you during appointments, and is more empathetic with your concerns. On average, patients under…
Did You Wash Your Hands?
I’ve been at a conference the last few days where scholars from around the world are discussing health literacy. It’s a subject much more complicated than just wondering at what level a…
Discovering MS Research
When talking about MS research, we tend to focus on drug development because improved therapies, and even the cure for MS, will come from pharmaceuticals. But what do we know about other…
A Look Inside MS Marketplace Projections
Do you ever stop and ponder the value of MS drugs? I’m not talking about if they work and the ways they improve our lives. I’m thinking of the COST of them and…
There’s an App (Maybe Too Many) for That!
How many hours do the pharmaceutical companies think we have in our day? I ask because almost all of them have come up with very slick tools to use, particularly mobile apps,…
#Sleeptember is Here!
What better time of year to talk about getting good sleep than heading into the fall season, which is followed by the dark days of winter? Although we are not furry creatures who curl…
